Publications

Population pharmacokinetic analysis of the IAPs antagonist Debio 1143 and its major metabolite in oncologic patients

Phase 1 Study of Debio 1143 with Concurrent Chemo-Radiotherapy in Locally Advanced Squamous Cell Carcinoma of the Head and Neck

FGFR selective inhibitor Debio1347 induces tumor regressions in FGFR2-altered gastric cancer PDX models

Activity of Debio 1452 against Staphylococcus spp. collected in 2013 / 2014

Activity of the novel Fabl inhibitor Debio 1452 against intracellular forms of susceptible and resistant S. aureus: comparison with linezolid,…

Efficacy and Safety Of AFN-1252, The First Staphylococcus-Specific Antibacterial Agent, in The Treatment of Acute Bacterial Skin And Skin Structure…

Clinical Safety, Pharmacokinetics and Early Evidence of Activity of The Oral IAPs Inhibitor Debio 1143 in Combination with Carboplatin and…

SMAC mimetic Debio 1143 synergizes with taxanes, topoisomerase inhibitors and bromodomain inhibitors to impede growth of lung adenocarcinoma cells

The radiosensitizing activity of the SMAC-mimetic, Debio 1143, is TNF-alpha-mediated in head and neck squamous cell carcinoma.